Mela Sciences (MELA) +83% premarket after the FDA issues an "approvable letter" for its medical...


Mela Sciences (MELA) +83% premarket after the FDA issues an "approvable letter" for its medical device that aims to help doctors more accurately diagnose melanoma. Previously the agency had called on the company to conduct a large new study of the MelaFind device, which already is approved for use in 27 European countries.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs